The UAE Country of Honor at Thessaloniki International Fair TIF 86: Minister of Economy Heads UAE’s Delegation to Greece with Extensive Government & Private-Sector Participation

Abu Dhabi – 07/09/2022,
- Picture is available at AP Images (http://www.apimages.com) -
The United Arab Emirates (UAE) will participate — with a high-ranking delegation headed by the UAE Minister of Economy, H.E. Abdulla Bin Touq Al Marri — in the Thessaloniki International Fair TIF 86, which will be held in Greece from 10 to 18 September 2022.
The UAE will serve as the Country of Honor at the 86th Thessaloniki International Fair (TIF) in Greece, participating with a prominent delegation that comprises 60 government and private-sector entities.
The delegation will showcase the country’s important economic developments, the latest UAE technology-related products, and the nation’s new economic sectors.
The UAE’s participation in TIF 86 comes in the context of the nation’s pursuit of attracting USD 150 billion in inward foreign investment over the next 9 years to become one of the top 10 global investment destinations — particularly in the New Economy sectors — by 2030.
The UAE’s participation in TIF 86 aims to boost cooperation with the business communities in Greece, the Balkans, and European markets to give momentum to economic development & mutual investments in the UAE and these countries. The UAE’s participation is set to make a lasting impression due to the strength of its delegation
- The UAE aims to create a successful knowledge-based economy and to create a world-class healthcare system.
- UAE is investing heavily in creating a world-leading regulatory framework for IT / AI ventures, providing infrastructure to build the best possible tech-investment ecosystem
- The UAE’s pharmaceutical market presents significant growth opportunities for multinational drug makers.
- The UAE Government is focused on more than doubling the contribution of industrial manufacturing to the UAE’s GDP to 25 percent.
Long version of this press release can be found at:
https://www.presseportal.de/nr/165110?langid=2
Contact:
Rana Elshorbagy
rana.elshorbagy@strategic.ae
Bilder

Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
INTERSPORT Austria acquires INTERSPORT Slovenia Group15.1.2026 15:16:10 CET | Press release
Strategic move strengthens market position in Central Europe, with over 500 locations in 12 countries and more than € 1 billion in sales
VORN Bioenergy announces appointments to leadership team15.1.2026 11:14:45 CET | Press release
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team.
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom
